IRs of Candida infection in the current study were similar to those reported following use of another IL-17A inhibitor in patients with PsO, PsA and axSpA [36], and although different members of the IL-17 inhibitor family demonstrate different rates of Candida infection [36, 44, 45], we demonstrate consistently low rates over long-term use with IXE. This evidence concerns the gene IL17A and candidiasis.